Estimating treatment effect on timed 25-foot walk in multiple sclerosis: A systematic review and meta-analysis.

• Tác giả: Byoung-Kab Kang, Haerang Kim, Kwijoo Kim, Kyung Suk Kim, Taehwan Kim, Jihoon Lee, Kyung-Eun Lee, Tae Yong Lee, Kwangyeon Oh, Nan Song, Soyoun Yang, Jiyeong Youn, Minju Yuk
• Ngôn ngữ: eng
• Ký hiệu phân loại: 922.945 *Hindus
• Thông tin xuất bản: Netherlands : Multiple sclerosis and related disorders , 2025
• Bộ sưu tập: NCBI
• ID: 713686

Tóm tắt

 BACKGROUND AND OBJECTIVES: Timed 25-foot walk (T25FW) is a common and reliable measure of ambulatory impairment in people with multiple sclerosis (MS). There is a lack of evidence evaluating the treatment effects on T25FW in MS. This study aimed to estimate treatment effects on T25FW in MS through a systematic review and meta-analysis. METHODS: From PubMed, Embase, and Cochrane Library databases, 41 articles were eligible for this study, including 21 parallel-arm and 20 single-arm studies. A multilevel meta-analysis summarized the comprehensive treatment effects on T25FW with odds ratios (OR) and standardized mean changes (SMC) for parallel- and single-arm studies, respectively. RESULTS: In the meta-analysis, the overall comprehensive treatment effect on T25FW was confirmed, showing a concurrent effect (OR=1.28
  95 % CI=1.10-1.48, P=0.0038) in parallel-arm studies and a longitudinal effect (SMC=0.20
  95 % CI=0.03-0.36, P=0.023) in single-arm studies. Specifically, ocrelizumab demonstrated the most concurrent effect (OR=1.60
  95 % CI=1.17-2.21, P=0.0036), though based on a single study with binary T25FW scores. On the other hand, fampridine had the most longitudinal effect (SMC=0.24
  95 % CI=0.12-0.36, P=0.0022), based on ten studies. CONCLUSION: In the current multilevel meta-analysis, we provided comprehensive treatment effects for T25FW in MS, confirming the better effects of ocrelizumab and fampridine.